Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has received FDA approval to market Humira as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis or JIA in patients four years of age and older.
Subscribe to our email newsletter
The approval is based on safety and efficacy results from a clinical study of JIA patients four to 17 years of age. According to the company, JIA is the sixth disease indication for which Humira has received approval since 2002.
Eugene Sun, vice president, global pharmaceutical clinical development of Abbott, said: “The approval of Humira provides an excellent option in the treatment of JIA. In addition to its efficacy in reducing the signs and symptoms of polyarticular JIA, we believe that children and their caretakers will appreciate the benefit of convenient every-other-week dosing that Humira offers.”